



PATENT
PC6947A/6970AGCB

10
1-16-91

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: STEPHEN P. GIBSON ET AL. : EXAMINER:
SERIAL NO.: 07/142,888 : E. PESELEV
FILED: JANUARY 11, 1988 : ART UNIT: 183
FOR: ANTIPARASITIC AGENTS AND PROCESS
FOR THEIR PREPARATION :

Hon. Commissioner of Patents and Trademarks
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.99

I hereby certify that this
correspondence is being
deposited with the United States
Postal Service as First Class mail
in an envelope addressed to:
Commissioner of Patents and
Trademarks, Washington, D.C.
20231, on this 11th day of
Dec. 19 90
By Roberto Lombardi

Sir:

Applicants herein make available to the Patent and
Trademark Office a copy of PTO-FB-A820 which lists
additional references cited by the Applicants, copies
of which are enclosed.

U.S. 4,134,973 discloses, inter alia, (1) certain
milbemycins, 13-hydroxy milbemycins and carbohydrate
derivatives thereof wherein the C-25 moiety is methyl
or ethyl and (2) processes for producing such
compounds.

U.S. 4,156,720 discloses, inter alia, certain
carbohydrate derivatives of milbemycins, 13-hydroxy
milbemycins wherein the C-25 moiety is methyl or ethyl
and processes for producing such compounds.

GB 2170499 discloses, inter alia, certain milbe-
mycins wherein the C-25 moiety is methyl or ethyl and a
process for producing such compounds.

1/90
M.2
(1/2)

EP 235085 discloses, inter alia, certain milbemycin derivatives wherein the C-25 moiety is methyl, ethyl, isopropyl or sec-butyl. The text of EP 235085 is in German and Applicants have been unable to find an English language equivalent. If the Examiner requires a translation thereof in order to consider the reference, Applicants will obtain and provide same to the Examiner.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 CFR 1.104(a). It is believed the Examiner will concur with Applicants' belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on Form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Dated: Dec. 11, 1990



Gregg C. Benson
Attorney for Applicants
Reg. No. 30,997
(203) 441-4901

Enclosures

Pfizer Inc.
Patent Dept.
Eastern Point Road
Groton, CT 06340